ReviewJournal of molecular and cellular cardiology2020
Coagulopathy in COVID-19: Focus on vascular thrombotic events.
Review in Journal of molecular and cellular cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.Frontiers in immunology · 2025Trial
- Changes in Adenosine Deaminase Activity and Endothelial Dysfunction after Mild Coronavirus Disease-2019.International journal of molecular sciences · 2023Article
- Changes and significance of vascular endothelial injury markers in patients with diabetes mellitus and pulmonary thromboembolism.BMC pulmonary medicine · 2023Article
- Lupus anticoagulants as a prospective independent predictor in COVID-19 patients.International journal of laboratory hematology · 2023Article
- Comparative Analysis of 198 SARS-CoV-2 Genomes from Iran and West Asia, February 2020 to December 2021.Iranian journal of pathology · 2023Article
- Transcriptional dynamics of granulocytes in direct response to incubation with SARS-CoV-2.FEBS open bio · 2023Article
- Elevated Serum Amyloid A Levels Contribute to Increased Platelet Adhesion in COVID-19 Patients.International journal of molecular sciences · 2022Article
- Association of periodontal therapy, with inflammatory biomarkers and complications in COVID-19 patients: a case control study.Clinical oral investigations · 2022Article
- The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022Review
- Early-stage COVID-19 pandemic observations on pulmonary embolism using nationwide multi-institutional data harvesting.NPJ digital medicine · 2022Article
- Surge in testicular torsion in pediatric patients during the COVID-19 pandemic.Journal of pediatric surgery · 2022Observational
- Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures.The European respiratory journal · 2022Article
- Periodontitis and coronavirus disease 2019.Periodontology 2000 · 2022Review
- Ependymal restricted diffusion and injury to the olfactory system on a ventriculoencephalitis associated with COVID-19.Journal of neurovirology · 2022Article
- SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease.Virology journal · 2022Article
- Vascular complications in 305 severely ill patients with COVID-19: a cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2022Article
- Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment.Chinese journal of integrative medicine · 2022Review
- COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks.International journal of biological macromolecules · 2021Review
- Posterior Reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature.Journal of neurology · 2021Review
- COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease.Molecular neurobiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.